Opus Genetics (IRD) Cash & Equivalents (2010 - 2026)

Opus Genetics (IRD) has reported Cash & Equivalents for 17 consecutive years, with $60.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 43.57% year-over-year to $60.0 million; the TTM figure through Mar 2026 stood at $60.0 million (up 43.57% YoY), while the FY2025 annual figure was $45.1 million, up 48.71% from the prior year.
• Cash & Equivalents rose to $60.0 million in Q1 2026 per IRD's latest filing, from $45.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $60.0 million in Q1 2026 and bottomed at $13.9 million in Q3 2022.
• Historically, Cash & Equivalents has averaged $37.1 million across 5 years, with a median of $40.0 million in 2023.
• Annual changes were most pronounced in 2023 — Cash & Equivalents soared 205.67% — and 2024, when it slumped 39.96%.
• Opus Genetics' Cash & Equivalents stood at $42.6 million in 2022, then grew by 18.45% to $50.5 million in 2023, then slumped by 39.96% to $30.3 million in 2024, then surged by 48.71% to $45.1 million in 2025, then jumped by 33.06% to $60.0 million in 2026.
• Business Quant data shows IRD's Cash & Equivalents at $60.0 million in Q1 2026, $45.1 million in Q4 2025, and $30.8 million in Q3 2025.